J. M. Wolf, “Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil”, Clin Biomed Res, vol. 43, nº 3, nov. 2023.